Tirzepatide is a dual GIP and GLP-1 receptor agonist approved by the FDA for type 2 diabetes management under the brand name Mounjaro and for chronic weight management under Zepbound. In 2026, list prices range from $900 to $1,100 per month, though manufacturer savings cards and insurance coverage can dramatically reduce out-of-pocket costs.
What Is Tirzepatide and How Does It Work?
Tirzepatide belongs to a relatively new class of injectable medications that activate two incretin hormone receptors simultaneously: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). This dual mechanism sets it apart from older GLP-1 receptor agonists like semaglutide, which targets only the GLP-1 pathway.
By activating both pathways, tirzepatide enhances insulin secretion in a glucose-dependent manner, suppresses glucagon, slows gastric emptying, and promotes a strong sense of satiety. Clinical trial data published in the New England Journal of Medicine and reviewed by the FDA demonstrated that patients using tirzepatide for weight management lost an average of 20 to 22 percent of their body weight over 72 weeks in the SURMOUNT-1 trial. For patients with type 2 diabetes in the SURPASS trials, A1C reductions of up to 2.58 percentage points were observed.
Eli Lilly manufactures tirzepatide and markets it under two brand names depending on the approved indication. Mounjaro carries FDA approval for glycemic control in adults with type 2 diabetes. Zepbound received FDA approval in November 2023 for chronic weight management in adults with a body mass index of 30 or greater, or 27 or greater with at least one weight-related comorbidity such as hypertension or sleep apnea. The underlying molecule is identical, but the approvals, labeling, and pricing structures differ in ways that matter significantly to patients and payers.
Tirzepatide Dosing and Available Strengths
Tirzepatide is administered as a once-weekly subcutaneous injection. It is available in six dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Most patients begin at the 2.5 mg starting dose for the first four weeks and then titrate upward every four weeks as tolerated. The 2.5 mg dose is considered a titration dose only and is not intended as a maintenance dose for either indication.
Each strength is available in both a single-dose pen and a vial with an auto-injector for self-administration. The pen format is the most common delivery method used in clinical practice. Understanding the dose you are prescribed matters financially, because the cost does not scale linearly with dose strength. In many pharmacy benefit structures, all strengths are priced at the same tier, which means a patient on 15 mg pays a similar copay as one on 5 mg — a nuance that can affect titration decisions in cost-sensitive situations.
How Much Does Tirzepatide Cost in 2026?
The cost figures we discuss here are derived from a combination of manufacturer-published list prices, pharmacy benefit manager formulary data, and aggregated pharmacy claims data analyzed by our research team at GLP-1 Cost Calculator. We cross-reference these figures quarterly against pricing databases and manufacturer announcements to keep our estimates current.
As of mid-2026, the average wholesale price (AWP) for a four-week supply of tirzepatide sits between approximately $1,050 and $1,100 for Mounjaro and between $960 and $1,040 for Zepbound, depending on dose strength and retail pharmacy. These AWP figures are the starting point insurers and pharmacy benefit managers use to negotiate, but they rarely reflect what any individual patient pays at the counter.
For patients with commercial insurance, the actual out-of-pocket cost depends on several factors: whether tirzepatide is on formulary, which tier it occupies, whether the prescribed indication is covered, and whether the patient has met their annual deductible. Patients with Medicaid coverage face a different landscape, as coverage and cost-sharing rules vary substantially by state. Medicare Part D coverage of tirzepatide for weight management specifically remains limited, though coverage for the diabetes indication has expanded across many plans.
To get a personalized estimate based on your specific plan and dose, use our GLP-1 Cost Calculator to see how your insurance and savings programs interact with your tirzepatide prescription.
Insurance Coverage for Tirzepatide: What You Need to Know
Insurance coverage for tirzepatide in 2026 remains inconsistent across payer types and indications. Understanding these distinctions can make the difference between paying $25 per month and $1,000 per month.
Commercial Insurance Coverage
Most large commercial insurance plans now include at least one formulation of tirzepatide on formulary for type 2 diabetes. Mounjaro is more broadly covered for diabetes than Zepbound is for obesity, reflecting the longstanding disparity in insurance coverage between metabolic disease management and weight loss. However, that gap has narrowed meaningfully in 2025 and 2026 as employer-sponsored health plans increasingly recognize the downstream cost savings of treating obesity with effective pharmacotherapy.
Coverage determinations for weight management purposes typically require prior authorization. Plans commonly require documented BMI thresholds, evidence of a weight-related comorbidity, documentation of previous weight loss attempts, and a prescribing physician's letter of medical necessity. Prior authorization denial rates for Zepbound remain higher than for Mounjaro, though step therapy requirements are increasingly driving patients toward tirzepatide after failing on older agents.
Medicare Coverage
Medicare Part D covers Mounjaro for type 2 diabetes under most plans as of 2026, but coverage of Zepbound for weight management under Medicare remains constrained. The Treat and Reduce Obesity Act, which would mandate Medicare coverage of FDA-approved anti-obesity medications, has seen renewed legislative activity, but as of the publication date of this article, no comprehensive mandate is yet in effect. Patients relying on Medicare should verify their specific Part D plan's formulary each year during the open enrollment period, as formulary placements change annually.
Medicaid Coverage
Medicaid coverage of tirzepatide varies by state. Some states have added both Mounjaro and Zepbound to preferred drug lists with modest cost-sharing. Others cover only the diabetes indication or have placed tirzepatide on non-preferred formulary tiers with higher cost-sharing. Patients on Medicaid should work directly with their prescribing provider and state Medicaid office to understand their options.
Manufacturer Savings Programs and Patient Assistance
Eli Lilly operates savings programs for both Mounjaro and Zepbound that can significantly reduce costs for eligible commercially insured patients. As of 2026, eligible patients with commercial insurance may pay as little as $25 to $150 per month through these programs, though eligibility criteria and maximum benefit amounts are subject to change.
For uninsured patients or those whose insurance does not cover tirzepatide, Eli Lilly also offers a patient assistance program called Lilly Cares. Income-based eligibility requirements apply, and patients may receive medication at no cost or reduced cost after a formal application process.
Compounded tirzepatide was available through certain 503A and 503B pharmacies during periods when FDA-approved versions were on the shortage list. As of 2026, the FDA has taken enforcement action against many compounders, and patients should be aware that compounded versions are not FDA-approved and carry different safety and efficacy considerations. The FDA's official drug shortage database at FDA.gov provides current shortage status information that is updated regularly.
Comparing Tirzepatide Costs to Other GLP-1 Medications
When evaluating tirzepatide against other GLP-1 medications, the cost comparison requires looking beyond the sticker price to clinical outcomes, dose equivalencies, and what each drug is approved to treat. Our methodology for comparing costs across GLP-1 agents uses a cost-per-percentage-point-of-A1C-reduction framework for diabetes and a cost-per-kilogram-of-weight-loss framework for obesity management, normalized across standard trial durations.
On that basis, tirzepatide compares favorably to semaglutide 2.4 mg (Wegovy) for weight management, given its superior average weight loss outcomes at comparable price points. For diabetes management, tirzepatide and once-weekly semaglutide (Ozempic) are closer in value, though tirzepatide demonstrates greater A1C reduction in head-to-head data from the SURPASS-CVOT trial. For a detailed side-by-side cost comparison across GLP-1 agents, visit our cost comparison tool on the GLP-1 Cost Calculator website.
Side Effects and Clinical Considerations Affecting Cost Planning
Understanding tirzepatide's side effect profile matters not only for health reasons but also for financial planning. The most common adverse effects are gastrointestinal in nature: nausea, vomiting, diarrhea, and constipation. These are most pronounced during the titration phase and typically diminish as the body adjusts to the medication.
Slower titration, sometimes extending the standard four-week titration period to eight weeks, is associated with better tolerability. Patients who experience significant gastrointestinal side effects may stay on lower doses longer, which extends the time on titration doses but does not necessarily increase cost under most benefit structures. Patients who discontinue tirzepatide due to side effects and then restart the medication may need to re-titrate, which means additional time at lower doses.
Serious but rare adverse events listed in the FDA-approved labeling for tirzepatide include pancreatitis, gallbladder disease, hypoglycemia in patients also using insulin or insulin secretagogues, acute kidney injury related to dehydration, and a black box warning for thyroid C-cell tumors based on rodent studies. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 are advised against using tirzepatide. Full prescribing information is available at FDA.gov.
How to Reduce Your Tirzepatide Costs in 2026
There are several practical strategies patients and caregivers can use to reduce tirzepatide costs. First, always check whether you qualify for the manufacturer savings card before paying full price or assuming your insurance is your only option. Second, ask your prescriber whether the diabetes indication or the weight management indication is more appropriate and whether that distinction affects your plan's coverage decisions. Third, work with a patient advocate or pharmacy benefits specialist if you receive a prior authorization denial — appeals are frequently successful when accompanied by thorough clinical documentation.
Fourth, consider whether a 90-day supply through mail-order pharmacy reduces your per-dose cost under your plan's benefit structure. Many plans offer lower cost-sharing for 90-day fills through preferred mail-order pharmacies. Fifth, if you are uninsured or underinsured, compare cash prices across multiple pharmacy chains using our GLP-1 Cost Calculator, which aggregates real-time cash pricing data to identify the lowest available price in your area.
The Outlook for Tirzepatide in 2026 and Beyond
Tirzepatide continues to be studied in additional indications beyond type 2 diabetes and obesity. Clinical trials are ongoing or have recently reported data in areas including heart failure with preserved ejection fraction, obstructive sleep apnea, non-alcoholic steatohepatitis, and metabolic dysfunction-associated steatotic liver disease. The FDA approved tirzepatide for sleep apnea reduction in adults with obesity in 2024, and that approval has opened new coverage avenues through some sleep medicine benefit structures.
As the patent landscape evolves over the next several years, the potential for generic or biosimilar versions of tirzepatide will eventually create competitive pricing pressure. However, small molecule GLP-1 agents and the complexity of biologics manufacturing mean that cost relief from biosimilar competition is unlikely before the late 2020s at the earliest. In the near term, patient access will continue to depend primarily on manufacturer savings programs, insurance negotiation outcomes, and evolving regulatory policy.
This content is for informational purposes only and does not constitute medical advice. GLP-1 medication costs and coverage vary by plan and individual. Consult your healthcare provider and pharmacist. Verify current information at FDA.gov.